TESARO to Announce First-Quarter 2018 Financial Results on May 3, 2018
April 19, 2018 16:15 ET
|
TESARO, Inc.
WALTHAM, Mass., April 19, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce first-quarter 2018 financial results on Thursday, May 3, 2018, after the close of the U.S. financial...
TESARO Summarizes TSR-042 Clinical Data Presented at AACR
April 16, 2018 09:00 ET
|
TESARO, Inc.
Activity of TSR-042 (anti-PD-1 antibody) monotherapy demonstrated in patients with MSI-high endometrial and non-small cell lung cancers Data support unique and convenient dosing scheduleRegulatory...
TESARO and Medison Enter Into Exclusive Distribution Agreement to Commercialize ZEJULA® in Israel
April 11, 2018 08:30 ET
|
TESARO, Inc.
Agreement covers all indications for ZEJULA, excluding prostate cancer ZUG, Switzerland and PETACH TIKVA, Israel, April 11, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an...
Data From TOPACIO Trial Reported at SGO Demonstrates Compelling Clinical Activity of ZEJULA in Combination With an Anti-PD-1 Antibody in Patients With Platinum Resistant/Refractory Ovarian Cancer
March 26, 2018 16:00 ET
|
TESARO, Inc.
Efficacy of niraparib in combination with an anti-PD-1 mAb surpasses historical efficacy benchmarks for PD-1 or PARP monotherapies in difficult-to-treat types of ovarian cancer, regardless of...
TESARO Announces Data Presentations at the 2018 American Association for Cancer Research Annual Meeting
March 14, 2018 16:50 ET
|
TESARO, Inc.
WALTHAM, Mass., March 14, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that data for ZEJULA, TSR-042 (anti-PD-1 antibody) and...
TESARO Announces Participation at Two Investor Conferences
March 01, 2018 16:15 ET
|
TESARO, Inc.
WALTHAM, Mass., March 01, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences....
TESARO Announces Fourth-Quarter and Full-Year 2017 Operating Results
February 27, 2018 16:05 ET
|
TESARO, Inc.
ZEJULA is the #1 PARP inhibitor for women with ovarian cancer in the U.S.2017 ZEJULA® net sales totaled $109 million during first nine months of commercial launchFocused clinical development program...
TESARO Announces Collaboration to Evaluate Combination of ZEJULA® (Niraparib) and Anti-PD-L1 Cancer Immunotherapy in Metastatic Bladder Cancer
February 26, 2018 15:00 ET
|
TESARO, Inc.
WALTHAM, Mass., Feb. 26, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has entered into a clinical collaboration with...
TESARO to Announce Fourth-Quarter 2017 Financial Results on February 27, 2018
February 02, 2018 09:48 ET
|
TESARO, Inc.
WALTHAM, Mass., Feb. 02, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce fourth-quarter 2017 financial results on Tuesday, February 27, 2018, after the close of the U.S. financial...
TESARO Announces Updates to the U.S. Prescribing Information for VARUBI® (rolapitant) Injectable Emulsion
January 12, 2018 17:30 ET
|
TESARO, Inc.
WALTHAM, Mass., Jan. 12, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has updated the VARUBI® (rolapitant) injectable...